TIMP4 Modulates ER-α Signalling in MCF7 Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tissue inhibitor of metalloprotease 4 (TIMP4) is linked to poor prognosis in various cancers, including breast cancer.
• The precise mechanisms by which TIMP4 influences breast cancer cell behavior remain largely unexplored.
• Understanding TIMP4's role is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To investigate the signalling pathways affected by TIMP4 in breast cancer cells.
• To elucidate the molecular mechanisms underlying TIMP4's contribution to cancer progression.
• To identify potential therapeutic targets modulated by TIMP4.

Main Methods:

• Human recombinant TIMP4 was administered to MCF7 breast cancer cells.
• RNA sequencing (RNASeq) was performed to analyze gene expression changes.
• Reverse transcription-polymerase chain reaction (RT-PCR) was used for validation of RNASeq findings.
• Network analyses were conducted to identify modulated signalling pathways.

Main Results:

• TIMP4 exposure led to the activation of oestrogen receptor alpha (ER-α), HIF1A, and TGF-β signalling pathways.
• FOXO3 signalling pathway was observed to be downregulated following TIMP4 treatment.
• Protein levels of ER-α were significantly increased in TIMP4-treated cells.
• Analysis revealed enrichment of oestrogen-binding sites in the promoters of TIMP4-upregulated genes.

Conclusions:

• TIMP4 modulates critical cancer-related signalling pathways in MCF7 breast cancer cells.
• The ER-α signalling cascade is significantly influenced by TIMP4.
• TIMP4's activation of ER-α signalling may contribute to its role in poor cancer prognosis.